Literature DB >> 22525626

[Club drugs].

Diogo Frasquilho Guerreiro1, Ana Lisa Carmo, Joaquim Alves da Silva, Rita Navarro, Carlos Góis.   

Abstract

Club drugs are the following substances: Methylenedioxymethamphetamine (MDMA); Methamphetamine; Lysergic Acid Diethylamide (LSD); Ketamine; Gamma-hydroxybutyrate (GHB) and Flunitrazepam. These substances are mainly used by adolescents and young adults, mostly in recreational settings like dance clubs and rave parties. These drugs have diverse psychotropic effects, are associated with several degrees of toxicity, dependence and long term adverse effects. Some have been used for several decades, while others are relatively recent substances of abuse. They have distinct pharmacodynamic and pharmacokinetic properties, are not easy to detect and, many times, the use of club drugs is under diagnosed. Although the use of these drugs is increasingly common, few health professionals feel comfortable with the diagnosis and treatment. The authors performed a systematic literature review, with the goal of synthesising the existing knowledge about club drugs, namely epidemiology, mechanism of action, detection, adverse reactions and treatment. The purpose of this article is creating in Portuguese language a knowledge data base on club drugs, that health professionals of various specialties can use as a reference when dealing with individual with this kind of drug abuse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22525626

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  2 in total

1.  Evaluation of Cytotoxic, Necrotic, Apoptotic, and Autophagic Effects of Methamphetamine and 3,4-Methylenedioxymethamphetamine on U-87 MG (Glial) and B104-1-1 (Neuronal) Cell Lines.

Authors:  Asieh Hosseini; Seyed Mohammad-Hossein Shetab-Boushehri; Seyed Vahid Shetab-Boushehri
Journal:  Neurotox Res       Date:  2022-07-15       Impact factor: 3.978

2.  Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial.

Authors:  Dongming Wang; Wenzhen Li; Yang Xiao; Wulong He; Weiquan Wei; Longyu Yang; Jincong Yu; Fujian Song; Zengzhen Wang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.